Citing an item in Forbes, Fiercepharma reports that drugs giant AstraZeneca has avoided a full-blown trial to protect its antipsychotic medication for bipolar disorder Seroquel. Teva Pharmaceutical hoped to market a generic version of this medication, which has a current US patent expiration date in September 2011, and commenced legal proceedings against AstraZeneca based on a "no inequitable conduct" challenge, but it has been reported that a federal court in New Jersey has given summary judgment in AstraZeneca's favour. A patent extension for specifically for paediatric use will extend AstraZeneca's protection to March 2012. Teva is believed to be considering an appeal against the court's ruling.
Wednesday, 2 July 2008
Teva challenge to Seroquel fails; paediatric extension granted
Citing an item in Forbes, Fiercepharma reports that drugs giant AstraZeneca has avoided a full-blown trial to protect its antipsychotic medication for bipolar disorder Seroquel. Teva Pharmaceutical hoped to market a generic version of this medication, which has a current US patent expiration date in September 2011, and commenced legal proceedings against AstraZeneca based on a "no inequitable conduct" challenge, but it has been reported that a federal court in New Jersey has given summary judgment in AstraZeneca's favour. A patent extension for specifically for paediatric use will extend AstraZeneca's protection to March 2012. Teva is believed to be considering an appeal against the court's ruling.
No comments:
Post a Comment